Rhythm Pharmaceuticals, Inc. Reports Larger Q3 Loss, Falls Short of Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Should l Buy RYTM?
Source: NASDAQ.COM
Quarterly Loss: Rhythm Pharmaceuticals reported a third-quarter loss of -$54.28 million, or -$0.82 per share, which is an increase from last year's loss of -$44.97 million, or -$0.73 per share.
Revenue Growth: The company's revenue rose by 54.3% to $51.30 million, up from $33.25 million in the same period last year.
Analyst Expectations: The reported loss missed analysts' expectations, who had anticipated earnings of -$0.73 per share.
Earnings Summary: Key earnings figures include a loss of -$54.28 million, an EPS of -$0.82, and revenue of $51.30 million for the quarter.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RYTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RYTM
Wall Street analysts forecast RYTM stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 98.070
Low
123.00
Averages
140.62
High
167.00
Current: 98.070
Low
123.00
Averages
140.62
High
167.00
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rhythm Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Rhythm Pharmaceuticals reported Q4 2025 IMCIVREE sales of $57.3 million, a 12% sequential increase, with total annual revenue reaching $194.8 million, approximately 50% higher than 2024, indicating robust market performance.
- Clinical Progress on Track: CEO Meeker noted that the Bivamelagon HO study showed 11 out of 14 patients achieving over 10% BMI reduction at 40 weeks, with plans to present 52-week data at a mid-year medical meeting, marking a smooth transition to Phase 3 trials.
- International Market Expansion: IMCIVREE is now available in over 25 countries, including 8 newly added markets, showcasing the company's growth potential globally, particularly among the estimated 5,000 to 8,000 HO patients in Japan.
- Positive Future Outlook: Management anticipates 2026 non-GAAP operating expenses to range from $385 million to $415 million, reflecting ongoing investments in clinical programs and confidence in future growth, while planning to have Bivamelagon Phase 3 trial drug supply ready by year-end 2026.
See More
RYTM Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: RYTM's 52-week low is $45.905 per share, while the high is $122.20, with the last trade at $91.99, indicating significant price volatility and reflecting market interest and investor sentiment changes.
- Technical Indicator Observation: The current price of $91.99 is close to the 52-week low, potentially prompting investors to reassess its future performance, especially as the price is below the 200-day moving average, suggesting short-term downside risks.
- Market Sentiment Impact: The fluctuations in RYTM's stock price may be influenced by overall market sentiment, particularly amid increasing economic uncertainty, leading investors to be more cautious, which could affect trading volume and price trends.
- Investor Focus: As RYTM's stock price approaches the 52-week low, investors may pay close attention to changes in its fundamentals and future earnings expectations to decide whether to buy or sell at the current price level.
See More
Rhythm Pharmaceuticals Reports Strong Q4 Results Exceeding Expectations
- Earnings Beat: Rhythm Pharmaceuticals reported a Q4 loss of $0.73 per share, better than the expected loss of $0.81, indicating improvements in cost control and operational efficiency, which bolstered investor confidence.
- Sales Growth: The company's sales reached $57.253 million, exceeding market expectations of $56.042 million, demonstrating strong global sales growth for IMCIVREE and further solidifying its market position in rare disease treatments.
- Future Growth Strategy: CEO David Meeker stated that the company is focused on long-term growth and is well-capitalized to achieve important commercial and clinical milestones in 2026, particularly in bringing IMCIVREE to patients with acquired HO in the U.S.
- Analyst Rating Upgrades: Analysts from Guggenheim and Citizens raised their price targets for Rhythm Pharmaceuticals from $140 and $167 to $143 and $176, respectively, reflecting optimistic market expectations regarding the company's future growth potential.
See More
Rhythm Pharma (RYTM) Earnings Call Transcript
See More
Rhythm Pharmaceuticals Set to Announce Q4 Earnings
- Earnings Announcement: Rhythm Pharmaceuticals is set to release its Q4 earnings report on February 26 before market open, with a consensus EPS estimate of -$0.78, reflecting an 8.3% year-over-year decline, which may impact investor sentiment.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $56.21 million, representing a 34.4% year-over-year increase, indicating the company's sales growth potential in the market, which could attract more investor interest in its future prospects.
- Performance Beat Record: Over the past year, Rhythm has beaten EPS estimates 75% of the time and revenue estimates 50% of the time, suggesting a degree of stability in financial performance and market confidence in the company.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and two downward revisions, while revenue estimates have experienced five upward revisions with no downward adjustments, reflecting analysts' optimistic outlook on the company's future performance.
See More
Overview of FDA Regulatory Developments
- BHA Safety Reassessment: On February 10, 2026, the FDA initiated a comprehensive reassessment of Butylated Hydroxyanisole (BHA) to evaluate its safety in food and food contact substances based on the latest scientific data, despite its classification as a potential human carcinogen in animal studies, which could affect consumer confidence in food safety.
- Hormone Therapy Labeling Updates: On February 12, 2026, the FDA approved labeling updates for six menopausal hormone therapy products, including Prometrium and Divigel, clarifying risk considerations and removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia, which may enhance market acceptance of these therapies.
- Innovative Device Approval: On the same day, the FDA approved Novocure's Optune Pax, a first-of-its-kind device for treating locally advanced pancreatic cancer, marking a significant technological advancement in cancer treatment and potentially providing new options for patients.
- Biotech Stocks Under Scrutiny: With upcoming FDA decisions in March 2026, biotech stocks are under market scrutiny, and investors should closely monitor the potential impacts of these decisions on related companies, which could trigger market volatility.
See More
Rhythm Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Rhythm Pharmaceuticals reported Q4 2025 IMCIVREE sales of $57.3 million, a 12% sequential increase, with total annual revenue reaching $194.8 million, approximately 50% higher than 2024, indicating robust market performance.
- Clinical Progress on Track: CEO Meeker noted that the Bivamelagon HO study showed 11 out of 14 patients achieving over 10% BMI reduction at 40 weeks, with plans to present 52-week data at a mid-year medical meeting, marking a smooth transition to Phase 3 trials.
- International Market Expansion: IMCIVREE is now available in over 25 countries, including 8 newly added markets, showcasing the company's growth potential globally, particularly among the estimated 5,000 to 8,000 HO patients in Japan.
- Positive Future Outlook: Management anticipates 2026 non-GAAP operating expenses to range from $385 million to $415 million, reflecting ongoing investments in clinical programs and confidence in future growth, while planning to have Bivamelagon Phase 3 trial drug supply ready by year-end 2026.
See More
RYTM Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: RYTM's 52-week low is $45.905 per share, while the high is $122.20, with the last trade at $91.99, indicating significant price volatility and reflecting market interest and investor sentiment changes.
- Technical Indicator Observation: The current price of $91.99 is close to the 52-week low, potentially prompting investors to reassess its future performance, especially as the price is below the 200-day moving average, suggesting short-term downside risks.
- Market Sentiment Impact: The fluctuations in RYTM's stock price may be influenced by overall market sentiment, particularly amid increasing economic uncertainty, leading investors to be more cautious, which could affect trading volume and price trends.
- Investor Focus: As RYTM's stock price approaches the 52-week low, investors may pay close attention to changes in its fundamentals and future earnings expectations to decide whether to buy or sell at the current price level.
See More
Rhythm Pharmaceuticals Reports Strong Q4 Results Exceeding Expectations
- Earnings Beat: Rhythm Pharmaceuticals reported a Q4 loss of $0.73 per share, better than the expected loss of $0.81, indicating improvements in cost control and operational efficiency, which bolstered investor confidence.
- Sales Growth: The company's sales reached $57.253 million, exceeding market expectations of $56.042 million, demonstrating strong global sales growth for IMCIVREE and further solidifying its market position in rare disease treatments.
- Future Growth Strategy: CEO David Meeker stated that the company is focused on long-term growth and is well-capitalized to achieve important commercial and clinical milestones in 2026, particularly in bringing IMCIVREE to patients with acquired HO in the U.S.
- Analyst Rating Upgrades: Analysts from Guggenheim and Citizens raised their price targets for Rhythm Pharmaceuticals from $140 and $167 to $143 and $176, respectively, reflecting optimistic market expectations regarding the company's future growth potential.
See More
Rhythm Pharma (RYTM) Earnings Call Transcript
See More
Rhythm Pharmaceuticals Set to Announce Q4 Earnings
- Earnings Announcement: Rhythm Pharmaceuticals is set to release its Q4 earnings report on February 26 before market open, with a consensus EPS estimate of -$0.78, reflecting an 8.3% year-over-year decline, which may impact investor sentiment.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $56.21 million, representing a 34.4% year-over-year increase, indicating the company's sales growth potential in the market, which could attract more investor interest in its future prospects.
- Performance Beat Record: Over the past year, Rhythm has beaten EPS estimates 75% of the time and revenue estimates 50% of the time, suggesting a degree of stability in financial performance and market confidence in the company.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and two downward revisions, while revenue estimates have experienced five upward revisions with no downward adjustments, reflecting analysts' optimistic outlook on the company's future performance.
See More
Overview of FDA Regulatory Developments
- BHA Safety Reassessment: On February 10, 2026, the FDA initiated a comprehensive reassessment of Butylated Hydroxyanisole (BHA) to evaluate its safety in food and food contact substances based on the latest scientific data, despite its classification as a potential human carcinogen in animal studies, which could affect consumer confidence in food safety.
- Hormone Therapy Labeling Updates: On February 12, 2026, the FDA approved labeling updates for six menopausal hormone therapy products, including Prometrium and Divigel, clarifying risk considerations and removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia, which may enhance market acceptance of these therapies.
- Innovative Device Approval: On the same day, the FDA approved Novocure's Optune Pax, a first-of-its-kind device for treating locally advanced pancreatic cancer, marking a significant technological advancement in cancer treatment and potentially providing new options for patients.
- Biotech Stocks Under Scrutiny: With upcoming FDA decisions in March 2026, biotech stocks are under market scrutiny, and investors should closely monitor the potential impacts of these decisions on related companies, which could trigger market volatility.
See More
